ArticleJTCVS structural and endovascular2026
Management of prosthetic pulmonary valve endocarditis should include the selective application of transcatheter pulmonary valve replacement.
Article in JTCVS structural and endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Objective: Prosthetic pulmonary valve endocarditis (PPVE) limits survival and quality of life in patients with repaired congenital heart disease. We describe patient outcomes with PPVE in a single center and the application of transcatheter pulmonary valve replacement (TPVR). Methods: We performed a single-center retrospective review of patients with PPVE from 2010 to 2022. Subjects were stratified by initial treatment: group 1 comprised surgical pulmonary valve replacement (SPVR), group 2 comprised TPVR, and group 3 comprised initial medical therapy without plans for upfront surgical or procedural intervention. Micro-organism data, posttreatment morbidity, length of stay, recurrence, and mortality are reported. Results: Seventy patients met inclusion criteria; 7% (group 2) underwent TPVR, and 80% of these patients underwent TPVR as a bridge to SPVR. No patients from group 2 had recurrence. Mortality was similar in the upfront SPVR and TPVR groups (group 1: 17.4%, group 2: 20%, group 3: 2.4%). In total, 71% of patients in group 3 eventually required elective SPVR or TPVR, with 25% of patients undergoing TPVR after clearance of blood cultures having recurrence compared with 7.1% of patients who underwent SPVR after clearance of blood cultures. Conclusions: TPVR is a viable bridge to SPVR in select patients with PPVE and may serve as destination therapy. Recurrence may be more common in patients requiring PVR after clearance of infection. Prospective studies of first-line TPVR as a strategy for bridge-to-surgery in select high risk patients and destination therapy in patients with resolution of bacteremia are needed to define treatment pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.